BioMarin Pharmaceutical Inc.(BMRN)Earnings, Financials & Key RatiosBioMarin Pharmaceutical Inc. (BMRN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a healthy liquidity profile with $2.2 billion in cash, the current P/E of 32.78 appears difficult to justify given the recent deceleration in top-line growth to 2.8%.
BioMarin Pharmaceutical Inc. (BMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BioMarin Pharmaceutical Inc. (BMRN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.76vs $0.94-19.1% | $766Mvs $753M+1.8% |
| Q1 2026 | Feb 23, 2026 | $0.24vs $0.17-241.7% | $875Mvs $834M+4.9% |
| Q4 2025 | Oct 27, 2025 | $0.12vs $0.15+180.0% | $776Mvs $823M-5.7% |
| Q3 2025 | Aug 4, 2025 | $1.44vs $0.86+67.2% | $825Mvs $762M+8.3% |
Recent stock market news and headlines for BioMarin Pharmaceutical Inc. (BMRN)
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.
Key metrics vs top competitors for BioMarin Pharmaceutical Inc. (BMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $60.35 | $11.61B | 33.53 | 12.87% | 10.83% | 5.94% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
BioMarin Pharmaceutical Inc. (BMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BioMarin Pharmaceutical Inc. (BMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Apr 27, 2026·SEC
Apr 23, 2026·SEC
Get notified when BMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioMarin Pharmaceutical Inc. (BMRN) stock FAQ — growth, dividends, profitability & financials explained
BioMarin Pharmaceutical Inc. (BMRN) reported $3.24B in revenue for fiscal year 2025. This represents a 270093% increase from $1.2M in 1998.
BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 12.9% over the past year. This is steady growth.
Yes, BioMarin Pharmaceutical Inc. (BMRN) is profitable, generating $268.7M in net income for fiscal year 2025 (10.8% net margin).
BioMarin Pharmaceutical Inc. (BMRN) has a return on equity (ROE) of 5.9%. This is below average, suggesting room for improvement.
BioMarin Pharmaceutical Inc. (BMRN) generated $767.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
